Archive for the ‘Treatment’ Category

More Bad News On Remdesivir: Some Vials Contain Glass

https://childrenshealthdefense.org/defender/remdesivir-recall-glass-particles-covid-hospital-protocol/?

Glass Particles Prompt Another Recall of Remdesivir, the Controversial Drug Hospitals Used to Treat COVID Patients

An investigation by Gilead, maker of remdesivir, confirmed the presence of glass, according to the company recall notice posted on the FDA website warning the contaminated vials can cause stroke and “even lead to death.”

by Brenda Baletti, Ph.D.
September 26, 2024
remdesivir bottles and word "recall"

Pharmaceutical giant Gilead recalled one batch of its COVID-19 antiviral drug Veklury, the brand name for remdesivir, after glass particles were discovered in vials of the drug, Newsweek reported.

A company investigation, prompted by a customer complaint, confirmed the presence of glass, according to the company recall notice posted on the U.S. Food and Drug Administration (FDA) website.

Gilead distributed the batch, identified as Veklury lot No. 47035CFA across the U.S. beginning on July 16. The batch isn’t set to expire until November 2025.

If a product containing glass is injected, it may result in localized swelling or, “the glass particulate can potentially travel, through the blood vessels, to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death,” the company warned in the recall notice.

Gilead said it is informing distributors and customers via a letter sent to UPS Next Day Air. The letter advises facilities that have the recalled drug to stop using it and return the vials to the company following the instructions in the letter.

Gilead said it has not received any reports of adverse events related to this lot.

The company didn’t say where the lots were manufactured or by whom and did not respond to The Defender’s request for comment on those questions.  (See link for article)

________________

**Comment**

Similarly to the fact COVID tests and gene therapy injections should ALL be recalled and destroyed with a public apology, Remdesivir has been nothing but a major problem since it was rolled out as part of the ‘Fauci Death Protocol.’ 

For more:

Going back to 1997, Donald Rumsfeld chaired the Board of Directors at Gilead and after 2001 he held share packages valued at $5-25 Million. Gilead originally developed Tamiflu. George P Shultz, US Secretary of State also was on the board. He sold stocks at a value of more than $7 million. CA governor’s Pete Wilson’s wife also sat on the board.

“‘I don’t know of any biotech company that’s’ so politically well-connected [as Gilead],‘ Andrew McDonald, of the analyst firm Think Equity Partners, told Fortune.” (Source: “Virus Mania, How the Medical Industry Continually Invents Epidemics Making Billion Dollar Profits At Our Expense”)

  • Approximately $70 million in U.S. taxpayer funding began Gilead’s partnership with the U.S. Army, Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) to develop remdesivir. Initially for treating Ebola, it failed to show benefit and was shelved. If remdesivir is used to treat COVID-19, Gilead shareholders, not the taxpayers, will profit.

Please remember:

  • There were more than 500 deaths in the first year of remdesivir usage.
  • There have been 20 deaths in 19 years of ivermectin usage.
  • The FDA, spurred by “multiple” reports of ivermectin ‘poisoning,’ lied when it put out a post on it causing “serious harm, seizures, coma, and even death”.  When the author inquired on how many is “multiple,” she was told FOUR.  Yet, the FDA had no trouble approving remdesivir which has caused far more deaths.
  • CDC also bad-mouthed ivermectin and pushed the “calls to the poison control center” narrative. The problem is they gave no data to support this claim.

Category:

Activism, Treatment, Viruses

AMA Lyme Disease: A Clinician Toolkit (Part 2)

I must have missed Part 1.  Here it is:  https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249

In short, the CDC gave the AMA 5M in taxpayer dollars to come up with an IDSA Toolkit to improve care for patients with prolonged symptoms and concerns about Lyme disease.

Hopefully you can see the inherent problems with this.  Once again, the wolf is being asked how to take care of the chickens.  Dr. Paul Auwaerter particularly appears to speak out of both sides of his mouth.

Further, the American Medical Association (AMA) is a completely corrupt, tyrannical institution.  It opposes free speech, instructs doctors to deceive, is behind persecuting doctors who think for themselves, was found GUILTY in a court of law of conspiring against chiropractic, and has completely monopolized medicine with the help of the Rockefellers.

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32919062?

American Medical Association Lyme Disease: A Clinician Toolkit (Part 2)

Carl Tuttle
Hudson, NH, United States
Sep 25, 2024

The letter below is a follow-up to the previous petition update: https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “pauwaert@jhmi.edu” <pauwaert@jhmi.edu>, “pgauwaerter@gmail.com” <pgauwaerter@gmail.com>
Cc: “cbb0@cdc.gov” <cbb0@cdc.gov>, “jjohnson@genevausa.org” <jjohnson@genevausa.org>, “theerhisamariee@gmail.com” <theerhisamariee@gmail.com>, “jaucott@jhmi.edu” <jaucott@jhmi.edu>, “jraitt1@stanford.edu” <jraitt1@stanford.edu>, “dclauw@med.umich.edu” <dclauw@med.umich.edu>, “john.leong@tufts.edu” <john.leong@tufts.edu>, “avindra.nath@nih.gov” <avindra.nath@nih.gov>, “charles.chiu@ucsf.edu” <charles.chiu@ucsf.edu>, “elliot.cowan@partnersindiagnostics.com” <elliot.cowan@partnersindiagnostics.com>, “beth.jaworski@nih.hhs.gov” <beth.jaworski@nih.hhs.gov>, “roger@lundquist.org” <roger@lundquist.org>, “rachele.hendricks.sturrup@duke.edu” <rachele.hendricks.sturrup@duke.edu>, “info@lymebiobank.org” <info@lymebiobank.org>, “lorrainejohnson@outlook.com” <lorrainejohnson@outlook.com>, “wendyadams1@gmail.com” <wendyadams1@gmail.com>, “Leith.States@hhs.gov” <Leith.States@hhs.gov>, “tindall.matt@gmail.com” <tindall.matt@gmail.com>, “stacie.hudgens@clinoutsolutions.com” <stacie.hudgens@clinoutsolutions.com>, “raymond_dattwyler@nymc.edu” <raymond_dattwyler@nymc.edu>, “timothy.sellati@globallymealliance.org” <timothy.sellati@globallymealliance.org>, “nklimas@nova.edu” <nklimas@nova.edu>, “kester@genevausa.org” <kester@genevausa.org>, “nicole@nicolemalachowski.com” <nicole@nicolemalachowski.com>, “marcom@genevausa.org” <marcom@genevausa.org>, “stephen.gluckman@pennmedicine.upenn.edu” <stephen.gluckman@pennmedicine.upenn.edu>, “epocratesMedia@athenahealth.com” <epocratesMedia@athenahealth.com>, “epocrates@athenahealth.com” <epocrates@athenahealth.com>, “achen@mathematica-mpr.com” <achen@mathematica-mpr.com>, “info@mathematica-mpr.com” <info@mathematica-mpr.com>, “pdecker@mathematica-mpr.com” <pdecker@mathematica-mpr.com>, “lwx1@cdc.gov” <lwx1@cdc.gov>, “frederick.chen@ama-assn.org” <frederick.chen@ama-assn.org>, “gmarx@cdc.gov” <gmarx@cdc.gov>, “acoyne@mathematica-mpr.com” <acoyne@mathematica-mpr.com>, “jconstantine@mathematica-mpr.com” <jconstantine@mathematica-mpr.com>, “ctrenholm@mathematica-mpr.com” <ctrenholm@mathematica-mpr.com>, “tbarnes@mathematica-mpr.com” <tbarnes@mathematica-mpr.com>, “sboudreau@mathematica-mpr.com” <sboudreau@mathematica-mpr.com>, “jdevallance@mathematica-mpr.com” <jdevallance@mathematica-mpr.com>, “sara.berg@ama-assn.org” <sara.berg@ama-assn.org>, “jack.resneck@ucsf.edu” <jack.resneck@ucsf.edu>, “jack.resneck@ama-assn.org” <jack.resneck@ama-assn.org>, “todd.unger@ama-assn.org” <todd.unger@ama-assn.org>, “jon.burkhart@ama-assn.org” <jon.burkhart@ama-assn.org>, “karen.kmetik@ama-assn.org” <karen.kmetik@ama-assn.org>, “sanjay.desai@ama-assn.org” <sanjay.desai@ama-assn.org>, “aaguilar@webmd.net” <aaguilar@webmd.net>, “DFlapan@Medscape.net” <DFlapan@Medscape.net>, “lkane@medscape.net” <lkane@medscape.net>, “gamiller@medscape.net” <gamiller@medscape.net>, “dolmos@webmd.net” <dolmos@webmd.net>, “sarah.wright@webmd.net” <sarah.wright@webmd.net>, “editor2@webmd.net” <editor2@webmd.net>, “kg@kirstengillibrand.com” <kg@kirstengillibrand.com>, “yzhang207@zju.edu.cn” <yzhang207@zju.edu.cn>, “jonathan.kanter@usdoj.gov” <jonathan.kanter@usdoj.gov>, “Antitrust.ATR@usdoj.gov” <Antitrust.ATR@usdoj.gov>, “gheltzer@mwe.com” <gheltzer@mwe.com>, “albert.sambat@usdoj.gov” <albert.sambat@usdoj.gov>, “ddutko@rustyhardin.com” <ddutko@rustyhardin.com>, “kspeer@rustyhardin.com” <kspeer@rustyhardin.com>, “katrina.rouse@usdoj.gov” <katrina.rouse@usdoj.gov>, “loppenheimer@oppenheimer-law.com” <loppenheimer@oppenheimer-law.com>

Date: 09/25/2024 9:20 AM EDT
Subject: Re: Improving Care for Patients with Prolonged Symptoms and Concerns about Lyme Disease: A Clinician Toolkit

Dr Auwaerter,

While we wait for your reply to my previous inquiry dated Sept 2nd, I would like to call attention to the following publication you coauthored with Johns Hopkins colleague Dr. Ying Zhang in 2014:

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library – PubMed
Jie Feng, Ting Wang, Wanliang Shi, Shuo Zhang, David Sullivan, Paul G Auwaerter & Ying Zhang

https://pubmed.ncbi.nlm.nih.gov/26038747/

Excerpt:

Findings that suggest the continued presence of B. burgdorferi in some form indicate that current Lyme disease treatment may not sufficiently eliminate B. burgdorferi persisters or that the immune system fails to clear persisting organisms or bacterial debris, which may be the underlying cause for those who suffer from unresolved Lyme disease symptoms.
Recent quote from Dr. Ying Zhang: (Now with Zhejiang University School of Medicine, Hangzhou, Zhejiang, China)

“We’re dealing with a very unique situation here. The current Lyme antibiotic does not completely eradicate Borrelia bacteria. We found this dandelion phenomenon. The mower is equivalent to the antibiotics, that chopped off the top part. But because the root, the possessor, is still there, they can grow back. You need drugs targeting both parts in order to more effectively cure this persistent form of the disease.”

Dr Auwaerter,

These findings appear to be missing from your recorded interview on the AMA website: “Toolkit to Improve Care for Patients with Prolonged Symptoms and Concerns about Lyme Disease”

For the record there are seven published studies finding Dapsone effective in treating chronic Lyme disease as reported by Dr. Richard Horowitz and colleagues: 1, 2, 3, 4, 5, 6, 7

In contrast Dr. Auwaerter, you were the lead author who published the hit piece in the Lancet Infectious Diseases condemning these physicians:

Antiscience and ethical concerns associated with advocacy of Lyme disease (2011)
https://pubmed.ncbi.nlm.nih.gov/21867956/

The 5-million-dollar grant given to the AMA by the CDC for this so-called “Clinician Toolkit” would have been better spent on validating antimicrobials that cure chronic Lyme. But then again if we had the correct treatment who would opt for Pfizer’s Lyme vaccine currently in phase III clinical trials ready to roll out in 2026?

Questions:

Which CDC employee/academic stands to benefit financially (patent royalties etc.) from the soon to be released OspA Pfizer Lyme vaccine and what role have these individuals played (if any) in the ongoing collusion to deny chronic Lyme disease? 

Carl Tuttle
Independent Researcher
Hudson, NH

Cc: Assistant Attorney General Jonathan Kanter, Attorney Katrina Rouse
Attorneys for the United States Antitrust Division

Assistant Attorney General Jonathan Kanter Announces Task Force on Health Care Monopolies and Collusion
https://www.justice.gov/opa/pr/assistant-attorney-general-jonathan-kanter-announces-task-force-health-care-monopolies-and

References:

1. Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections.
https://pubmed.ncbi.nlm.nih.gov/37764145/

2. Effect of dapsone alone and in combination with intracellular antibiotics against the biofilm form of B. burgdorferi.
https://pubmed.ncbi.nlm.nih.gov/32993780/

3. Efficacy of Short-Term High Dose Pulsed Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-Infections: A Report of Three Cases and Literature Review.
https://pubmed.ncbi.nlm.nih.gov/35884166/

4. Combining Double-Dose and High-Dose Pulsed Dapsone Combination Therapy for Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome and Co-Infections, Including Bartonella: A Report of 3 Cases and a Literature Review.
https://pubmed.ncbi.nlm.nih.gov/38792737/

5. Efficacy of Double-Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases and Retrospective Chart Review.
https://pubmed.ncbi.nlm.nih.gov/33105645/

6. Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1.
https://pubmed.ncbi.nlm.nih.gov/30863136/

7. Precision Medicine: The Role of the MSIDS Model in Defining, Diagnosing, and Treating Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome and Other Chronic Illness: Part 2.
https://pubmed.ncbi.nlm.nih.gov/30400667/
Previous inquiry to Auwaerter dated Sept 2nd:
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/32867249

Category:

Activism, Lyme, research, Treatment

Resolving Persistent Spike Protein Syndrome

https://townsendletter.com/resolving-persistent-spike-protein-syndrome/

Resolving Persistent Spike Protein Syndrome

Thomas E. Levy, MD, JD
Orthomolecular Medicine News Service

6/1/23

Article Excerpts:

As the acute cases of COVID have continued to decline, the prevalence of the Persistent Spike Protein (PSP) syndrome has continued to increase. The spike protein is that part of the COVID pathogen that attaches to ACE2 receptors throughout the body and permits the entry of the entire virus into the newly infected cell. There appear to be no cells, tissues, or organs in the body that are completely spared from this PSP attack once enough of it has been introduced into the body.

The persistent presence of the spike protein has been shown to be secondary to the inability to completely resolve a bout of COVID (chronic COVID or long-haul COVID) as well as the spike protein exposure from mRNA inoculation(s). And as more time has passed, the PSP syndrome following one or more mRNA shots has emerged as the most common reason for PSP, especially following a booster injection. Not surprisingly, the likelihood of developing a PSP syndrome relates directly to the total amount of spike protein exposure, and the amounts delivered by repeated inoculations substantially exceed the amounts that result from incompletely resolved cases of COVID.

The goal of any therapy designed to eliminate a chronic spike protein presence in the body needs to address its presence in the blood, its presence on the many ACE2 binding sites throughout the body, its presence inside the cells, and the mechanisms that allow it to replicate itself and keep it from being eliminated completely in the body. It has been shown that the sickest of PSP patients have intact spike protein circulating in the blood.1 

Multiple autopsy studies have revealed the presence of spike protein throughout the body, without any particular areas being spared.2,3

By itself, the spike protein is also toxic. As all toxins ultimately inflict damage by oxidizing biomolecules needed for normal metabolic function, any effective PSP protocol needs to include significant antioxidative capacity in order to repair damaged (oxidized) biomolecules. Spike protein has been shown to induce inflammation (acute oxidative stress) even without resulting in viral infection.4

Bio-Oxidative Therapies

While any therapy that can eradicate an infectious agent must involve its destruction via enhanced oxidation, the most prominent of these therapies involve the appropriate application of:

  • Vitamin C (multiple modalities)
  • Hydrogen peroxide (multiple modalities)
  • Ozone (multiple modalities)
  • Ultraviolet blood irradiation
  • Hyperbaric oxygen

While still not widely appreciated, these bio-oxidative therapies have been curing acute infectious diseases for very many years now.  (See link for article & references)

________________

**Comment**

Dr. Levvy states that a good protocol for PSP should include:

  • Ozone autohemotherapy, followed by
  • IV vitamin C (50 to 150 grams daily); or any oral form in the highest doses possible
  • IV or oral hydrocortisone (25 to 50 mg) in the IV or with the first oral dose of vitamin C
  • Ultraviolet blood irradiation if available
  • Hydrogen peroxide nebulization
  • Methylene blue, 25 to 50 mg two or three times daily
  • Proteolytic enzymes (bromelain, NAC, nattokinase)

Category:

Supplements, Treatment, Viruses

Benefits of Ozone on Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis

https://petermcculloughmd.substack.com/p/benefits-of-ozone-on-mortality-in?

Benefits of Ozone on Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis

Small Studies Found Benefit Yet Adjunctive Therapy Not Advanced to Large, Multicenter Trials

Sep 17, 2024

By Peter A. McCullough, MD, MPH

I attended an integrative medicine meeting recently and one of the speakers said that ozone was one of the most important tools in his practice. While this is a very broad topic with > 4000 papers listed in the National Library of Medicine with the MESH term “ozone therapy,” Hu et al briefly summarized:

“Ozone is a molecule composed of three oxygen atoms and a component of the atmosphere in nature, which has a strong oxidizing action. Ozone has a high-energy, variable molecular structure under normal temperature and is quickly and spontaneously decomposed into O2 and a single oxygen atom (O). It has strong activity in oxidation and a strong bactericidal effect on bacteria and viruses.10,11  Ozone therapy inactivates bacteria by disrupting their cell envelope through oxidation of phospholipids and lipoproteins, inhibits fungi growth, damages the capsid of viruses, and upsets the reproductive cycle by disrupting the virus-to-cell contact with peroxidation.12  Oxygen-ozone therapy causes an increase in the rate of red blood cell glycolysis, causing the stimulation of 2,3-diphosphoglycerate, which leads to an increase in oxygen released to the tissues.13”

Innovative physicians, from many parts of the world trialed ozone in hospitalized patients some of whom had 4-6 weeks in the hospital with acute COVID-19. Shang et al performed a meta-analysis of very small studies…. (See link for article)

_______________

https://pubmed.ncbi.nlm.nih.gov/36513208/

Benefits of ozone on mortality in patients with COVID-19: A systematic review and meta-analysis

Wenli Shang1, Yan Wang2, Guizuo Wang1, Dong Han3

Abstract

Background: The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. Ozone therapy has long been used in the treatment of a variety of infectious diseases, probably through its antioxidant properties and the supply of oxygen to hypoxic tissues. This systematic review and meta-analysis aimed to determine the efficacy of ozone on mortality in patients with COVID-19.

Methods: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Prospective controlled trials on treatment of COVID-19 with ozone, compared with placebo or blank, were reviewed. Studies were pooled to risk ratios (RRs) and weighted mean differences (WMDs), with 95% confidence intervals (CIs).

Results: Eight trials (enrolling 371 participants) met the inclusion criteria. Ozone therapy showed significant effects on mortality (RR 0.38, 95% CI 0.17-0.85; P = 0.02), length of hospital stay (WMD -1.63 days, 95% CI -3.05 to -0.22 days; P = 0.02), and polymerase chain reaction (PCR) positivity (RR 0.07, 95% CI 0.01-0.34; P = 0.001).

Conclusions: Ozone therapy significantly reduced mortality, PCR positivity, and length of stay in hospitalized patients with COVID-19. Ozone therapy should be considered for COVID-19 patients.

https://pubmed.ncbi.nlm.nih.gov/33169118/

No abstract available, but go here for the commentary:  https://www.cell.com/the-innovation/fulltext/S2666-6758(20)30063 1returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666675820300631%3Fshowall%3Dtrue
All patients also were given antiviral agents and three were also treated with steroids.

Category:

research, Treatment, Viruses

Remdesivir: What You Should Know

Dr. Vernon Coleman: Remdesivir – What You Must Know

“Please share this article with everyone you know. And please send or show copies of this article to every doctor and nurse you can reach. “

Lioness of Judah Ministry
Aug 29, 2024

By Dr. Vernon Coleman

Remdesivir is described as a `broad spectrum antiviral drug’. It is a RNA polymerase inhibitor which disrupts the production of vital RNA. It is said to prevent the multiplication of SARS-CoV-2.

Remdesivir was introduced for the treatment of covid-19 patients who were in hospital suffering from covid-19, with or without pneumonia. It is still being widely used. I have been researching and writing about drugs since 1970 and I am appalled at the way that it now appears that in some countries some hospitals and doctors (and even nurses) are now routinely giving remdesivir to patients – particularly elderly patients – who do not have severe signs and/or symptoms of the flu or a flu-like viral infection. You can form your own opinion on whether remdesivir ever has a value by reading the following information.

1. Remdesivir is officially used to treat patients who have symptoms of covid-19 or who have covid-19 according to the discredited PCR test which no one with any functioning brain tissue should use. Anyone who uses a PCR test to diagnose covid-19 is a moron and you can tell them I said that. Please see my two recent articles (on http://www.vernoncoleman.com) entitled `PCR: How the PCR test has killed millions’ and `The PCR test can kill you’. A positive PCR test does NOT prove that you have covid-19, dandruff, chilblains, covid-19 or anything else.

2. Remdesivir seems to be very, very popular with very, very stupid doctors who seem to think it is a panacea for all illnesses. If their Mercedes or BMW breaks down they probably give the car a shot of remdesivir.

3. Remdesivir is given directly into a vein. Doctors who tell you that giving drugs via a vein is an entirely safe procedure are stupid. No medical procedure is entirely safe. Giving drugs by injection into a blood stream requires skill and experience to avoid dangers.

4. The brand name of remdesivir is Veklury. (Brand names always begin with an initial capital but generic names are all lower case.) If you are being given Veklury, you are being given remdesivir.

5. Remdesivir should be prescribed by a doctor and given under a doctor’s supervision. (Nurses may wear stethoscopes round their necks, but they are not doctors.)

6. Remdesivir must be given slowly over a period of between 30 minutes and 120 minutes.

7. Hospital patients are usually given remdesivir once a day for up to 10 days.

8. Patients not in hospital are usually given remdesivir once a day for three days.

9. Patients who are given remdesivir MUST have regular blood tests to check that their livers are functioning properly. If a doctor gives remdesivir without doing regular liver function tests he or she is dangerous and, in my opinion, should have their medical licence revoked.

10. Liver function tests MUST be done before remdesivir is prescribed. Any doctor who does not do liver tests before starting treatment should be sacked and have their medical licence revoked.

11. Severe renal toxicity has been noted in animal studies. (Some doctors claim that animal studies are irrelevant. I agree. But why do them if they are irrelevant?)

12. No one should be given remdesivir if they are allergic to it.

13. Anyone who has ever had liver disease or kidney disease should inform their doctor if he/she suggests prescribing remdesivir.

14. Anyone who is pregnant or breastfeeding should tell their doctor. The UK’s National Institute for Health and Care Excellence (NICE) says that the safety of covid-19 antiviral treatment during pregnancy has NOT been established.

15. Remdesivir may interact, to your disadvantage, with other prescription medicines, with over the counter medicines, with vitamins and with herbal products. Doctors who prescribe remdesivir must ask patients about all the medicines they are taking.

16. Remdesivir has received a number of reviews on drugs.com, and of the reviews listed on 24th August 2024, 19.38% or reviewers had a `positive experience’ but 47% had a `negative experience’.

17. According to the journal `Science’, in October 2020,`The World Health Organisation’s Solidarity Trial showed that remdesivir does not reduce mortality or the time covid-19 patients take to recover.’ And `A second, smaller placebo-controlled study of remdesivir on hospitalised covid-19 patients in China, published online by The Lancet on 29th April 2020, found no statistically significant benefit from the treatment – and the antiviral surprisingly had no impact on levels of the coronavirus’. I find it difficult to see why the FDA, the EU and the UK’s drug regulator all approved remdesivir, though they appear to have done so without worrying too much about the research showing that it was pretty useless.

18. Side effects which may occur when remdesivir is injected include: fast, pounding heartbeats; trouble in breathing; wheezing, shivering, itching, sweating, facial swelling, severe headache, a feeling of being about to pass out. Side effects subsequently may include nausea and abnormal liver function tests.

19. NICE reports that there are twelve drugs with which remdesivir inter-reacts. Any doctor prescribing remdesivir should know of these interactions – which are listed on the NICE website. So, for example, the manufacturers advise that patients avoid taking remdesivir with chlorquine, hydroxychloroquine and phenytoin. I cannot put a link to the NICE website because such links are not allowed. The list of side effects below was NOT taken from the NICE website. (Since it is a public sector body and paid for by taxpayers, you’d think that NICE would be delighted to share information about drug dangers wouldn’t you?)

20. Side effects which can occur in patients taking remdesivir may include:

Back pain
Bleeding
Blistering
Burning
Chest tightness
Chills
Coldness
Cough
Dark coloured urine (a possible sign of liver problems)
Difficulty in swallowing
Discolouration of skin
Fast heartbeat
Feeling of pressure
Fever

Flushing
Headache
Hives and itching
Infection
Inflammation
Light coloured stools (a possible sign of liver problems)
Lumps
Nausea and vomiting
Numbness
Pain
Puffiness or swelling of the eyelids or around the eyes, face, lips or tongue
Redness

Scarring
Seizures
Skin rash
Soreness
Stinging
Stomach pain, continuing
Swelling
Tenderness
Tingling
Trouble breathing
Ulceration
Unusual tiredness or weakness
Yellow eyes or skin (a possible sign of liver problems)

You will be relieved to know that not all patients would be expected to have all of these side effects, though a number of these side effects are classified as `common’.

Please share this article with everyone you know. And please send or show copies of this article to every doctor and nurse you can reach. Send copies to your GP and your local hospital.

Unlike NICE I like to share the information I obtain, and unlike YouTube and the mainstream media I believe that the truth should not be censored and must be shared as widely as possible. I suspect that this article will be suppressed and hidden by Google et al. And I am banned from all media (mainstream and online) so please help share this article.

Copyright Vernon Coleman August 2024

NOTE
My first two books `The Medicine Men’ and `Paper Doctors’ dealt with dishonesty and corruption in medicine. `The Medicine Men’ dealt with the relationship between doctors and the drug industry. `Paper Doctors’ dealt with medical research. Both were published in the 1970s and attracted much praise at the time (though not from the pharmaceutical industry or the medical establishment). You can purchase them both from the bookshop on www.vernoncoleman.com

The Defender just came out with two articles on how ‘huge’ financial incentives led hospitals to tragically use COVID treatments that killed patients, which included remdesivir and ventilators.

For more:

Category:

Treatment, Viruses